Clinical perspectives of PARP inhibitors

Keyphrases

• Additional Indications 14%
• Antitumor Agents 28%
• Cardiopulmonary Bypass 14%
• Cardiovascular Disease 14%
• Cell Injury 14%
• Chronic Use 14%
• Clinical Application 14%
• Clinical Development 14%
• Clinical High Risk 14%
• Clinical Outcomes 14%
• Clinical Perspective 100%
• Clinical Potential 14%
• Clinical Trials 14%
• Cytotoxicity 14%
• Diabetes Complications 14%
• DNA Repair 14%
• Double-edged Sword 14%
• Experimental Therapeutics 14%
• Human Disease 14%
• Inflammatory Cells 14%
• Inflammatory Diseases 14%
• Ischemia-reperfusion Injury 14%
• Life-limiting Conditions 14%
• Long-term Adverse Effects 14%
• Myocardial Infarction 14%
• Neurodegeneration 14%
• Neuroinflammation 14%
• Organ Damage 14%
• PARP Inhibitor (PARPi) 100%
• Patient with Tumor 14%
• Pharmacological Inhibitors 14%
• Poly(ADP-ribose) Polymerase 71%
• Poor Prognosis 14%
• Potential Risk 14%
• Severe Disease 14%
• Temozolomide 14%
• Therapeutic Effect 14%
• Thoracic Aortic Surgery 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Aneurysm 14%
• Anticarcinogen 28%
• Cardiovascular Disease 14%
• Cerebrovascular Accident 14%
• Clinical Trial 14%
• Cytoprotective Agent 14%
• Cytotoxicity 14%
• Diabetic Complication 14%
• Disease 42%
• Heart Infarction 14%
• Inflammatory Disease 14%
• Ischemia 14%
• Neoplasm 14%
• Nerve Degeneration 14%
• Nervous System Inflammation 14%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 71%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor 100%
• Organ Injury 14%
• Side Effect 14%
• Temozolomide 14%
• Therapeutic Effect 14%